Antibodies as Mediators of Brain Pathology

Trends in Immunology

Volumn 36, Issue 11, 2015, Pages 709-724

  Brimberg, Lior ^a   Mader, Simone ^a   Fujieda, Yuichiro ^a   Arinuma, Yoshiyuki ^a   Kowal, Czeslawa ^a   Volpe, Bruce T ^a   Diamond, Betty ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI P ANTIBODY; ANTIBODY; AUTOANTIBODY; MATERNAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN DISEASE; COGNITIVE DEFECT; DISEASE ASSOCIATION; HEART ATRIUM SEPTUM DEFECT; HUMAN; NONHUMAN; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; BRAIN; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ANTIBODIES; BRAIN; HUMANS;

EID: 84946716823     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.09.008     Document Type: Review

References (161)

1. Mazina V., et al. Epigenetics of autism-related impairment: copy number variation and maternal infection. J. Dev. Behav. Pediatr. 2015, 36:61-67.
2. Rivest S. Regulation of innate immune responses in the brain. Nat. Rev. Immunol. 2009, 9:429-439.
3. Diamond B., et al. Brain-reactive antibodies and disease. Annu. Rev. Immunol. 2013, 31:345-385.
4. Deverman B.E., Patterson P.H. Cytokines and CNS development. Neuron 2009, 64:61-78.
5. Petermann F., Korn T. Cytokines and effector T cell subsets causing autoimmune CNS disease. FEBS Lett. 2011, 585:3747-3757.
6. Cox C.J., et al. Brain human monoclonal autoantibody from sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine D2 receptor: implications in human disease. J. Immunol. 2013, 191:5524-5541.
7. Brimberg L., et al. Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology 2012, 37:2076-2087.
8. Engelhardt B. Development of the blood-brain barrier. Cell Tissue Res. 2003, 314:119-129.
9. Engelhardt B. Neuroscience. Blood-brain barrier differentiation. Science 2011, 334:1652-1653.
10. Jessen N.A., et al. The glymphatic system: a beginner's guide. Neurochem. Res. 2015, Published online May 7, 2015. 10.1007/s11064-015-1581-6.
11. Louveau A., et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015, 523:337-341.
12. Aspelund A., et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 2015, 212:991-999.
13. Bauer H.C., et al. Neovascularization and the appearance of morphological characteristics of the blood-brain barrier in the embryonic mouse central nervous system. Brain Res. Dev. Brain Res. 1993, 75:269-278.
14. Ben-Zvi A., et al. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature 2014, 509:507-511.
15. Braniste V., et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci. Transl. Med. 2014, 6:263ra158.
16. Simister N.E. Placental transport of immunoglobulin G. Vaccine 2003, 21:3365-3369.
17. Banks W.A., et al. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995, 2:241-248.
18. Tsao N., et al. Tumour necrosis factor-alpha causes an increase in blood-brain barrier permeability during sepsis. J. Med. Microbiol. 2001, 50:812-821.
19. Ballabh P., et al. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 2004, 16:1-13.
20. Zhang Y., Pardridge W.M. Rapid transferrin efflux from brain to blood across the blood-brain barrier. J. Neurochem. 2001, 76:1597-1600.
21. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7:715-725.
22. Montagne A., et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015, 85:296-302.
23. Methia N., et al. ApoE deficiency compromises the blood brain barrier especially after injury. Mol. Med. 2001, 7:810-815.
24. Hafezi-Moghadam A., et al. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am. J. Physiol. Cell Physiol. 2007, 292:C1256-C1262.
25. Hultman K., et al. The APOE varepsilon4/varepsilon4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients. J. Cereb. Blood Flow Metab. 2013, 33:1251-1258.
26. Cerletti A., et al. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J. Drug Target. 2000, 8:435-446.
27. Kroll S., et al. Control of the blood-brain barrier by glucocorticoids and the cells of the neurovascular unit. Ann. N. Y. Acad. Sci. 2009, 1165:228-239.
28. Gesuete R., et al. Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling. J. Neurochem. 2012, 123(Suppl. 2):75-85.
29. Serres S., et al. Magnetic resonance imaging reveals therapeutic effects of interferon-beta on cytokine-induced reactivation of rat model of multiple sclerosis. J. Cereb. Blood Flow Metab. 2013, 33:744-753.
30. Ni C., et al. Interferon-gamma safeguards blood-brain barrier during experimental autoimmune encephalomyelitis. Am. J. Pathol. 2014, 184:3308-3320.
31. Veldhuis W.B., et al. Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. J. Cereb. Blood Flow Metab. 2003, 23:1060-1069.
32. Niemela J., et al. IFN-β regulates CD73 and adenosine expression at the blood-brain barrier. Eur. J. Immunol. 2008, 38:2718-2726.
33. Stone L.A., et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol. 1995, 37:611-619.
34. Kowal C., et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:19854-19859.
35. Kowal C., et al. Cognition and immunity; antibody impairs memory. Immunity 2004, 21:179-188.
36. Huerta P.T., et al. Immunity and behavior: antibodies alter emotion. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:678-683.
37. Mallard C. Innate immune regulation by toll-like receptors in the brain. ISRN Neurol. 2012, 2012:701950.
38. Tuor U.I., et al. Functional magnetic resonance imaging of tonic pain and vasopressor effects in rats. Magn. Reson. Imaging 2002, 20:707-712.
39. Abbott N.J. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 2004, 45:545-552.
40. Roth J., et al. Signaling the brain in systemic inflammation: role of sensory circumventricular organs. Front. Biosci. 2004, 9:290-300.
41. Kabat E.A., et al. Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am. J. Med. 1948, 4:653-662.
42. Serafini B., et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14:164-174.
43. Solimena M., et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N. Engl. J. Med. 1988, 318:1012-1020.
44. Alaedini A., et al. Immune cross-reactivity in celiac disease: anti-gliadin antibodies bind to neuronal synapsin I. J. Immunol. 2007, 178:6590-6595.
45. Gini B., et al. Novel autoantigens recognized by CSF IgG from Hashimoto's encephalitis revealed by a proteomic approach. J. Neuroimmunol. 2008, 196:153-158.
46. Nashi E., et al. The role of B cells in lupus pathogenesis. Int. J. Biochem. Cell Biol. 2010, 42:543-550.
47. Bradl M., et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 2009, 66:630-643.
48. Bravo-Zehnder M., et al. Anti-ribosomal P protein autoantibodies from patients with neuropsychiatric lupus impair memory in mice. Arthritis Rheumatol. 2015, 67:204-214.
49. Hahn B.H. Antibodies to DNA. N. Engl. J. Med. 1998, 338:1359-1368.
50. DeGiorgio L.A., et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 2001, 7:1189-1193.
51. Gaynor B., et al. Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1955-1960.
52. Faust T.W., et al. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:18569-18574.
53. Vo A., et al. Regional brain metabolism in a murine systemic lupus erythematosus model. J. Cereb. Blood Flow Metab. 2014, 34:1315-1320.
54. Mackay M., et al. Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. Lupus Sci. Med. 2015, 2:e000074.
55. Chang E.B.V., et al. Selective impairment of spatial cognition caused by autoantibodies to the N-methyl-D-aspartate receptor. EBioMedicine 2015, 2:753-762.
56. Lapteva L., et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2505-2514.
57. Omdal R., et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 2005, 12:392-398.
58. Hanly J.G., et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum. 2008, 58:843-853.
59. Harrison M.J., et al. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2006, 54:2515-2522.
60. Husebye E.S., et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2005, 64:1210-1213.
61. Kozora E., et al. Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. J. Neurol. Sci. 2010, 295:87-91.
62. Petri M., et al. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J. Rheumatol. 2010, 37:2032-2038.
63. Arinuma Y., et al. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008, 58:1130-1135.
64. Hirohata S., et al. Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res. Ther. 2014, 16:R77.
65. Yoshio T., et al. IgG anti-NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells. Arthritis Rheum. 2013, 65:457-463.
66. Matus S., et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J. Exp. Med. 2007, 204:3221-3234.
67. Elkon K.B., et al. Lupus autoantibodies target ribosomal P proteins. J. Exp. Med. 1985, 162:459-471.
68. Katzav A., et al. Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression). J. Autoimmun. 2008, 31:393-398.
69. Katzav A., et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum. 2007, 56:938-948.
70. Segovia-Miranda F., et al. Pathogenicity of lupus anti-ribosomal P antibodies: role of cross-reacting neuronal surface P antigen in glutamatergic transmission and plasticity in a mouse model. Arthritis Rheumatol. 2015, 67:1598-1610.
71. Bonfa E., et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N. Engl. J. Med. 1987, 317:265-271.
72. Isshi K., Hirohata S. Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1996, 39:1483-1490.
73. Nagai T., et al. Anti-ribosomal P protein antibody induces Th1 responses by enhancing the production of IL-12 in activated monocytes. Mod. Rheumatol. 2011, 21:57-62.
74. Madaio M.P. Lupus autoantibodies 101: one size does not fit all; however, specificity influences pathogenicity. Clin. Exp. Immunol. 2003, 131:396-397.
75. Hadjivassiliou M., et al. The humoral response in the pathogenesis of gluten ataxia. Neurology 2002, 58:1221-1226.
76. Lennon V.A., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
77. Lennon V.A., et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202:473-477.
78. Roemer S.F., et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194-1205.
79. Sorensen A., et al. Astrocytes, but not olfactory ensheathing cells or Schwann cells, promote myelination of CNS axons in vitro. Glia 2008, 56:750-763.
80. Marignier R., et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010, 133:2578-2591.
81. Palace J., et al. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 2010, 67:1016-1017.
82. Wingerchuk D.M., et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015, 85:177-189.
83. Wingerchuk D.M., et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
84. Waters P., et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch. Neurol. 2008, 65:913-919.
85. Waters P.J., et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012, 78:665-671. discussion 669.
86. Marignier R., et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology 2013, 80:2194-2200.
87. Takahashi T., et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007, 130:1235-1243.
88. Mader S., et al. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS ONE 2010, 5:e10455.
89. Jarius S., Wildemann B. The history of neuromyelitis optica. J. Neuroinflammation 2013, 10:8.
90. Kim H.J., et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015, 84:1165-1173.
91. Saji E., et al. Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann. Neurol. 2013, 73:65-76.
92. Nishiyama S., et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 2009, 72:1960-1961.
93. Sabater L., et al. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J. Neuroimmunol. 2009, 215:31-35.
94. Pohl M., et al. Pathogenic T cell responses against aquaporin 4. Acta Neuropathol. 2011, 122:21-34.
95. Mader S., et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J. Neuroinflammation 2011, 8:184.
96. Bennett J.L., et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 2009, 66:617-629.
97. Saadoun S., et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133:349-361.
98. Misu T., et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol. 2013, 125:815-827.
99. Kowarik M.C., et al. The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. J. Neuroinflammation 2015, 12:19.
100. Chihara N., et al. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS ONE 2013, 8:e83036.
101. Pohl M., et al. T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathol. Commun. 2013, 1:85.
102. Jones M.V., et al. Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica. Acta Neuropathol. Commun. 2015, 3:28.
103. Kinoshita M., et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem. Biophys. Res. Commun. 2009, 386:623-627.
104. Kitic M., et al. Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats. Acta Neuropathol. Commun. 2013, 1:5.
105. Bradl M., Lassmann H. Experimental models of neuromyelitis optica. Brain Pathol. 2014, 24:74-82.
106. Palmeira P., et al. IgG placental transfer in healthy and pathological pregnancies. Clin. Dev. Immunol. 2012, 2012:985646.
107. Singalavanija S., et al. Neonatal lupus erythematosus: a 20-year retrospective study. J. Med. Assoc. Thai. 2014, 97(Suppl. 6):S74-S82.
108. Hacohen Y., et al. Fetal acetylcholine receptor inactivation syndrome: a myopathy due to maternal antibodies. Neurol. Neuroimmunol. Neuroinflamm. 2015, 2:e57.
109. Vinet E., et al. Neurodevelopmental disorders in children born to mothers with systemic lupus erythematosus. Lupus 2014, 23:1099-1104.
110. Lahita R.G. Systemic lupus erythematosus: learning disability in the male offspring of female patients and relationship to laterality. Psychoneuroendocrinology 1988, 13:385-396.
111. McAllister D.L., et al. The influence of systemic lupus erythematosus on fetal development: cognitive, behavioral, and health trends. J. Int. Neuropsychol. Soc. 1997, 3:370-376.
112. Ross G., et al. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch. Pediatr. Adolesc. Med. 2003, 157:397-402.
113. Urowitz M.B., et al. Neurocognitive abnormalities in offspring of mothers with systemic lupus erythematosus. Lupus 2008, 17:555-560.
114. Comi A.M., et al. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J. Child Neurol. 1999, 14:388-394.
115. Lee J.Y., et al. Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat. Med. 2009, 15:91-96.
116. Wang L., et al. Female mouse fetal loss mediated by maternal autoantibody. J. Exp. Med. 2012, 209:1083-1089.
117. Vinet E., et al. Increased male-to-female ratio among children born to women with systemic lupus erythematosus: comment on the article by Lockshin et al. Arthritis Rheum. 2013, 65:1129.
118. Jagota P., et al. Transplacental transfer of NMDA receptor antibodies in an infant with cortical dysplasia. Neurology 2014, 82:1662-1663.
119. Brimberg L., et al. Brain-reactive IgG correlates with autoimmunity in mothers of a child with an autism spectrum disorder. Mol. Psychiatry 2013, 18:1171-1177.
120. Braunschweig D., et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Transl. Psychiatry 2013, 3:e277.
121. Croen L.A., et al. Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study. Biol. Psychiatry 2008, 64:583-588.
122. Zimmerman A.W., et al. Maternal antibrain antibodies in autism. Brain Behav. Immun. 2007, 21:351-357.
123. Singer H.S., et al. Prenatal exposure to antibodies from mothers of children with autism produces neurobehavioral alterations: a pregnant dam mouse model. J. Neuroimmunol. 2009, 211:39-48.
124. Bauman M.D., et al. Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. Transl. Psychiatry 2013, 3:e278.
125. Dalton P., et al. Maternal neuronal antibodies associated with autism and a language disorder. Ann. Neurol. 2003, 53:533-537.
126. Martin L.A., et al. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav. Immun. 2008, 22:806-816.
127. Braunschweig D., et al. Maternal autism-associated IgG antibodies delay development and produce anxiety in a mouse gestational transfer model. J. Neuroimmunol. 2012, 252:56-65.
128. Camacho J., et al. Embryonic intraventricular exposure to autism-specific maternal autoantibodies produces alterations in autistic-like stereotypical behaviors in offspring mice. Behav. Brain Res. 2014, 266:46-51.
129. Martinez-Cerdeno V., et al. Prenatal exposure to autism-specific maternal autoantibodies alters proliferation of cortical neural precursor cells, enlarges brain, and increases neuronal size in adult animals. Cereb. Cortex 2014, Published online December 22, 2014. 10.1007/10.1093/cercor/bhu291.
130. Atladottir H.O., et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 2009, 124:687-694.
131. Braunschweig D., et al. Behavioral correlates of maternal antibody status among children with autism. J. Autism Dev. Disord. 2012, 42:1435-1445.
132. Saadoun S., et al. Neuromyelitis optica IgG causes placental inflammation and fetal death. J. Immunol. 2013, 191:2999-3005.
133. Igel C., et al. Neuromyelitis optica in pregnancy complicated by posterior reversible encephalopathy syndrome, eclampsia and fetal death. J. Clin. Med. Res. 2015, 7:193-195.
134. Reuss R., et al. A woman with acute myelopathy in pregnancy: case outcome. BMJ 2009, 339:b4026.
135. Bloom O., et al. Generation of a unique small molecule peptidomimetic that neutralizes lupus autoantibody activity. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10255-10259.
136. Shams'ili S., et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003, 126:1409-1418.
137. Graus F., et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J. Clin. Oncol. 1997, 15:2866-2872.
138. B and AMPA receptor antibodies: a case series. J. Neurol. Neurosurg. Psychiatry 2015, 86:965-972.
139. Gozzard P., et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study. Neurology 2015, 85:235-239.
140. Orange D., et al. Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. Arch. Neurol. 2012, 69:1132-1140.
141. Lai M., et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann. Neurol. 2009, 65:424-434.
142. Saiz A., et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008, 131:2553-2563.
143. Dalmau J., et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011, 10:63-74.
144. v1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010, 133:2734-2748.
145. Murinson B.B., Guarnaccia J.B. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008, 71:1955-1958.
146. Kastrup O., et al. Atypical paraneoplastic brainstem encephalitis associated with anti-Ri-antibodies due to thymic carcinoma with possible clinical response to immunoglobulins. Eur. Neurol. 2001, 45:285-287.
147. Graus F., et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001, 124:1138-1148.
148. Monstad S.E., et al. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin. Exp. Immunol. 2006, 144:53-58.
149. Lukacs S., et al. Rare association of anti-Hu antibody positive paraneoplastic neurological syndrome and transitional cell bladder carcinoma. Case Rep. Urol. 2012, 2012:724940.
150. Yamamoto T., Tsuji S. [Anti-Ma2-associated encephalitis and paraneoplastic limbic encephalitis]. Brain Nerve 2010, 62:838-851. (in Japanese).
151. Kirvan C.A., et al. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat. Med. 2003, 9:914-920.
152. O'Connor K.C., et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat. Med. 2007, 13:211-217.
153. Pleasure D. Diagnostic and pathogenic significance of glutamate receptor autoantibodies. Arch. Neurol. 2008, 65:589-592.
154. Hughes E.G., et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J. Neurosci. 2010, 30:5866-5875.
155. Cohen-Kashi Malina K., et al. Autoantibodies against an extracellular peptide of the GluR3 subtype of AMPA receptors activate both homomeric and heteromeric AMPA receptor channels. Neurochem. Res. 2006, 31:1181-1190.
156. Dalakas M.C., et al. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 2000, 55:1531-1535.
157. Geis C., et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010, 133:3166-3180.
158. Hadjivassiliou M., et al. Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. Neurology 2006, 66:373-377.
159. Lai M., et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010, 9:776-785.
160. Lancaster E., et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann. Neurol. 2011, 69:303-311.
161. Schiess N., Pardo C.A. Hashimoto's encephalopathy. Ann. N. Y. Acad. Sci. 2008, 1142:254-265.